A Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in PONV

NCT ID: NCT06170476

Last Updated: 2024-07-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 200 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-11-10
• Study Completion Date: 2024-05-15

Brief Summary

This is a multicenter, randomized, double-blind, placebo-controlled Dose-Finding study. About 200 subjects undergoing elective laparoscopic abdominal or gynecological surgery are planned to be enrolled and randomized into four groups by a ratio of 1:1:1:1.

Conditions

Postoperative Nausea and Vomiting

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

HSK21542-60μg

Group Type: EXPERIMENTAL

HSK21542-60μg

Intervention Type: DRUG

HSK21542 injection of 60 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;

HSK21542-120μg

Group Type: EXPERIMENTAL

HSK21542-120μg

Intervention Type: DRUG

HSK21542 injection of 120 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;

HSK21542-180μg

Group Type: EXPERIMENTAL

HSK21542-180μg

Intervention Type: DRUG

HSK21542 injection of 180 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

A placebo was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;

Interventions

HSK21542-60μg

HSK21542 injection of 60 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;

Intervention Type: DRUG

HSK21542-120μg

HSK21542 injection of 120 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;

Intervention Type: DRUG

HSK21542-180μg

HSK21542 injection of 180 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;

Intervention Type: DRUG

Placebo

A placebo was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age ≥18 and ≤75 years old, male or female;

2. The American Society of Anesthesiologists (ASA) Class I-III;

3. 18 kg/m2 ≤ BMI ≤ 40 kg/m2;

4. Hospitalized subjects scheduled to undergo elective laparoscopic abdominal or gynecological surgery under general anesthesia for an expected anesthetic time of ≥ 1 h;

5. Subjects with intermediate or high risk (score ≥ 2 points) experiencing PONV judged by the investigator using the Apfel simplified risk score;

6. Subjects who agree to participate in the trial and voluntarily sign the Informed Consent Form (ICF);

Exclusion Criteria

Prior and concomitant diseases

1. History or evidence of any of the following diseases prior to screening:

1. Respiratory diseases: severe chronic obstructive pulmonary disease, acute exacerbation of chronic obstructive pulmonary disease, severe airway stenosis, large pharyngolaryngeal mass, (broncho) tracheoesophageal fistula or airway tear, and serious respiratory tract infection within 2 weeks prior to screening;

2. Central nervous system disorders: subjects with epilepsy, Parkinson's disease, or other central nervous system diseases causing nausea and vomiting, such as craniocerebral injury, intracranial space-occupying lesions, intracranial aneurysms, etc.;

3. Cardiovascular diseases: subjects with uncontrolled hypertension [systolic blood pressure (SBP) ≥170 mmHg and/or diastolic blood pressure (DBP) ≥105 mmHg without treatment with antihypertensive medication, or SBP ≥160 mmHg and/or DBP ≥100 mmHg after treatment with antihypertensive medications], serious cardiac insufficiency ( the New York Heart Association [NYHA] Grade III-IV), unstable angina pectoris, acute myocardial infarction, severe arrhythmia, history of tachycardia/bradycardia requiring medical treatment, Grade II-III atrioventricular block (excluding pacemaker use) within 6 months prior to screenin;

4. Digestive disorders: subjects with intestinal obstruction or other digestive diseases that may cause nausea and vomiting as judged by the investigator;

5. Patients with a confirmed diagnosis of vestibular function disorder, excluding travel sickness (including but not limited to peripheral vestibular syndrome, central vestibular syndrome, etc.);

6. Subjects with a history of significant and chronic dizziness.

Prior and concomitant medications

2. Any of the following medications or treatments have been used at screening:

1. Subjects who have received antiemetics/medications with antiemetic effects within 24 h before the start of surgery or who have used antiemetics/drugs with antiemetic effects before the start of surgery for no more than 5 half-lives (calculated as the longest time);

2. Subjects with neoplasm malignant treated with chemotherapy within 4 weeks prior to screening;

Laboratory and other tests

3. Laboratory test indicators at screening meet the following criteria:

1. White blood cell count < 3.0 × 109/L;

2. Platelet count < 80 × 109/L;

3. Hemoglobin< 70 g/L;

4. Prolongation of prothrombin time (PT) exceeding the upper limit of normal for 3 seconds;

5. Prolongation of activated partial thromboplastin time (APTT) exceeding the upper limit of normal for 10 seconds;

6. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) > 3 × ULN;

7. Total bilirubin > 2 × ULN;

8. Blood creatinine > 2 × ULN;

9. Fasting serum glucose≥ 11.1 mmol/L;

Other conditions

4. Subjects anticipated to require continued endotracheal intubation after the end of surgery;

5. Subjects anticipated to require the insertion of nasal or oral gastric tubes after the end of surgery;

6. Subjects with a history of serious drug allergies or those allergic to the investigational drugs specified in the protocol;

7. Subjects with a history of drug abuse, drug addiction, or alcoholism within 3 months prior to screening, where alcoholism is defined as consuming > 2 units of alcohol on average daily (1 unit = 360 mL of beer with 5% alcohol, 45 mL of liquor with 40% alcohol or 150 mL of wine);

8. Subjects with nausea, retching, or vomiting within 24 h prior to induction of anesthesia (except for those caused by bowel preparation);

9. Subjects who have participated in any investigational trial (defined as receiving investigational drug or placebo) within 3 months prior to screening;

10. Female subjects who are pregnant or breastfeeding; female or male subjects of child-bearing potential are unwilling to use contraception throughout the entire study period and for 3 months after the study completion;

11. Subjects judged by the investigator to be unsuitable for participating in this clinical trial for any other factors.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sichuan Provincial People's Hospital

OTHER

Sponsor Role: lead

Responsible Party

Mengchang Yang

Deputy Chief Physician

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Sichuan Provincial People's Hospital

Sichuan, , China

Countries

China

Other Identifiers

HSK21542-IIT-01

Identifier Type: -

Identifier Source: org_study_id